



Editorial

Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision

Thorsten H. Ecke ^{1,2,*}, Florence Le Calvez-Kelm ³ and Thomas Otto ^{4,5}

¹ Department of Urology, HELIOS Hospital Bad Saarow, 15526 Bad Saarow, Germany

² Department of Urology, Universitätsmedizin Berlin-Charité, 10098 Berlin, Germany

³ International Agency for Research on Cancer (IARC), 69372 Lyon, France; lecalvezf@iarc.fr

⁴ Department of Urology, Rheinland Klinikum Neuss, 41464 Neuss, Germany; thomas.otto@rheinlansklinikum.de

⁵ University Hospital Essen, 45147 Essen, Germany

* Correspondence: thorsten.ecke@helios-kliniken.de or thorsten.ecke@charite.de; Tel.: +49-33631-72267; Fax: +49-33631-73136

Citation: Ecke, T.H.; Le Calvez-Kelm, F.; Otto, T. Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision. *Int. J. Mol. Sci.* **2022**, *23*, 5620. <https://doi.org/10.3390/ijms23105620>

Received: 10 May 2022

Accepted: 12 May 2022

Published: 17 May 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

After the successful publication of three Special Issues devoted to highlighting novel scientific research results in the field of bladder cancer and their clinical implications, we are now directing our efforts towards a fourth edition which will aim at compiling innovative research strategies that will ultimately guide and support clinicians in the decision-making process for targeted bladder cancer therapies.

Urothelial carcinoma is a fascinating tumor type characterized by marked tumor heterogeneity. This heterogeneity poses particular challenges for routine clinical practice and research. Research on urothelial carcinoma is currently speeding up—much more than in the years before. Methodological developments achieved in recent years, particularly in the area of high-throughput analyses, have contributed to a better understanding of the biology and heterogeneity of urothelial carcinoma, which has led to the development of new biomarkers and approaches for targeted therapy. Accordingly, this fourth edition includes many new chapters on molecular characterization, urothelial carcinogenesis and potential clinical applications.

Cystoscopy and imaging systems are still considered the gold standard for the detection and monitoring of bladder cancer as they have shown unequal combined overall sensitivity and specificity. However, they still have a limited sensitivity in detecting small lesions of the urinary tract. For this reason, urine cytology is still the most widely used complementary non-invasive test for the detection and surveillance of bladder cancer. Despite its high specificity of around 86%, the limitation of this method lies in its low sensitivity of approximately 50% [1], especially in detecting low-grade tumors [2,3]. Moreover, subjectivity and lack of uniformity in reporting the results of cytology examinations still exist despite the recent effort to better classify urine cytology results as per the Paris System guidelines [4]. Urine biomarkers have been developed and commercialized, but due to performance inconsistencies or cost considerations, none of them have been recommended by international guidelines for bladder cancer clinical management [5,6]. Therefore, to date, with the absence of reliable cost-effective urinary biomarkers, the confirmation of suspected carcinomas of the urinary tract and the subsequent life-long surveillance for relapse are still being undertaken by cystoscopic examinations, which represents a significant cost burden on healthcare systems [7].

In contrast to other urine markers, cytology is still recommended in bladder cancer diagnosis and surveillance for recurrence [8]. However, the development of nomograms integrating clinical parameters and potential promising urinary-based tumor markers

could, in theory, provide a cost-effective alternative to cystoscopy, therefore improving clinical management during primary detection of bladder cancer and follow-up [9].

Novel markers or combinations of existing tumor markers could significantly contribute to more precise diagnosis and tumor subclassifications as well as facilitating therapeutic decision making. The classification of bladder tumors based on grade and stage alone is suboptimal in predicting the biological behavior and in guiding the choice of treatment, especially in high-risk cases [10–12].

The molecular subtyping of bladder cancer based on its transcriptional features has been well characterized after its initial introduction in 2014 [13–15]. In particular, muscle-invasive tumors have been categorized into basal and luminal subtypes such as the molecular breast cancer subtypes originally described by Perou et al. [16], which have been subsequently shown to be predictive of clinical outcomes. In this line, basal types of muscle-invasive bladder cancer have been associated with shorter disease-specific and overall survival, presumably because patients with these cancers tended to have more invasive and metastatic disease at presentation [14].

The Lund study included both NMIBC and MIBC and described five expression subclasses with some presenting features that overlapped with luminal and basal subtypes of MIBC [17]. The UROMOL study, which focused on NMIBC only, described three subclasses (some overlapping features of the Lund classes) that showed prognostic significance [18]. There are now three accepted classifications that use different nomenclatures for bladder tumors, and it is critical to evaluate which signatures provide the best clinical utility, especially knowing that they appear to be promising for targeted therapies as some have shown differences in biological behavior and chemotherapy sensitivity [19]. In addition, as transcriptional profile similarities have been observed between bladder cancer and breast cancer subtypes, for which targeted therapies are well established [14,15], these therapeutic approaches may be successfully applied to treat specific bladder cancer patients. For instance, protein expressions of markers for basal (CK5/6, CK14, CD 40) and luminal subtypes (CK20, GATA3, ER β , Uroplakin II, HER2/neu, FGFR3) have been identified.

In addition to transcriptional molecular subtypes, DNA methylation profiles and copy number alterations have defined bladder cancer subtypes that may have some relevant prognostic implications. It is therefore expected that a multi-omics integrated approach could refine the molecular subtyping of bladder cancer, eventually providing the best clinical relevance [20]. Innovative research strategies should also help unveil unclear bladder cancer mechanisms. In a case report of an atypical bladder cancer patient initially presenting with a low-grade tumor that evolved to metastasis and subsequent death, “postmortem” pathological and molecular data were used to better characterize the subtype that could explain the poor prognosis and identify potential targets in critical pathways that may have led to better directed therapies and improved prognosis [21]. Altogether, this shows how research projects integrating molecular characterization of bladder tumors contribute to refining our understanding of bladder carcinogenesis that is essential to develop prognostication assays and target therapies. Early molecular analysis of bladder tumors will enable clinicians to choose the most adapted treatment and timely monitor treatment response and adapt it in case of an absence or incomplete response, for example, via dual blockade of FGFR and ERBB signaling.

In conclusion, there is an urgent and tremendous need for clinical markers that can reliably predict the recurrence and progression of bladder cancer; these markers will likely contribute to establishing better personalized treatments. Molecular staging of urological tumors will allow selecting cases that will require systemic and/or target treatments [22,23].

The editors thank all submitting authors for their efforts and time spent on each manuscript. The lead editor would like to thank all editors for the time spent in reviewing, assigning reviews and commenting on the submitted manuscripts. As the editorial team, we hope that this Special Issue will prove useful in planning future bladder cancer research studies.

Funding: This research received no external funding.

Conflicts of Interest: Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.

References

- Reid, M.D.; Osunkoya, A.O.; Siddiqui, M.T.; Looney, S.W. Accuracy of grading of urothelial carcinoma on urine cytology: An analysis of interobserver and intraobserver agreement. *Int. J. Clin. Exp. Pathol.* **2012**, *5*, 882–891.
- Yafi, F.A.; Brimo, F.; Steinberg, J.; Aprikian, A.G.; Tanguay, S.; Kassouf, W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. *Urol. Oncol.* **2015**, *33*, e25–e31.
- Lotan, Y.; Roehrborn, C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. *Urology* **2003**, *61*, 109–118; discussion 118.
- Barkan, G.A.; Wojcik, E.M.; Nayar, R.; Savic-Prince, S.; Quek, M.L.; Kurtucz, D.F.I.; Rosenthal, D.L. The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology. *Acta Cytol.* **2016**, *60*, 185–197.
- Schmitz-Dräger, B.J.; Droller, M.; Lokeshwar, V.B.; Lotan, Y.; Hudson, M.A.; van Rhijn, B.W.; Marberger, M.J.; Fradet, Y.; Hemstreet, G.P.; Malmstrom, P.-U.; et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: The WHO/ICUD consensus. *Urol. Int.* **2015**, *94*, 1–24.
- Barocas, D.A.; Boorjian, S.A.; Alvarez, R.D.; Downs, T.M.; Gross, C.P.; Hamilton, B.D.; Kobashi, K.C.; Lipman, R.R.; Lotan, Y.; Ng, C.K.; et al. Microhematuria: AUA/SUFU Guideline. *J. Urol.* **2020**, *204*, 778–786.
- Svatek, R.S.; Hollenbeck, B.K.; Holmäng, S.; Lee, R.; Kim, S.P.; Stenzl, A.; Lotan, Y. The economics of bladder cancer: Costs and considerations of caring for this disease. *Eur. Urol.* **2014**, *66*, 253–262.
- Babjuk, M.; Bohle, A.; Burger, M.; Capoun, O.; Cohen, D.; Compérat, E.M.; Hernández, V.; Kaasinen, E.; Palou, J.; Rouprêt, M.; et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. *Eur. Urol.* **2017**, *71*, 447–461.
- Meisl, C.J.; Karakiewicz, P.I.; Einarsson, R.; Koch, S.; Hallmann, S.; Weiß, S.; Hemdan, T.; Malmström, P.-U.; Styrke, J.; Sherif, A.; et al. Nomograms including the UBC® Rapid test to detect primary bladder cancer based on a multicentre dataset. *BJU Int.* **2021**. doi:10.1111/bju.15677.
- Theodorescu, D.; Wittke, S.; Ross, M.M.; Walden, M.; Conaway, M.; Just, I.; Mischak, H.; Frierson, H.F. Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis. *Lancet Oncol.* **2006**, *7*, 230–240.
- Sanchez-Carbayo, M.; Cordon-Cardo, C. Molecular alterations associated with bladder cancer progression. *Semin Oncol.* **2007**, *34*, 75–84.
- Mhawech-Fauceglia, P.; Cheney, R.T.; Schwaller, J. Genetic alterations in urothelial bladder carcinoma: An updated review. *Cancer* **2006**, *106*, 1205–1216.
- Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature* **2014**, *507*, 315–322.
- Choi, W.; Porten, S.; Kim, S.; Willis, D.; Plimack, E.R.; Hoffman-Censits, J.; Roth, B.; Cheng, T.; Tran, M.; Lee, I.-L.; et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. *Cancer Cell* **2014**, *25*, 152–165.
- Damrauer, J.S.; Hoadley, K.A.; Chism, D.D.; Fan, C.; Tiganelli, C.J.; Wobker, S.E.; Yeh, J.J.; Milowsky, M.I.; Iyer, G.; Parker, J.S.; et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 3110–3115.
- Perou, C.M.; Sørlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; et al. Molecular portraits of human breast tumours. *Nature* **2000**, *406*, 747–752.
- Sjödahl, G.; Lauss, M.; Lövgren, K.; Chebil, G.; Gudjonsson, S.; Veerla, S.; Patschan, O.; Aine, M.; Fernö, M.; Ringnér, M.; et al. A molecular taxonomy for urothelial carcinoma. *Clin. Cancer Res.* **2012**, *18*, 3377–3386.
- Hedegaard, J.; Lamy, P.; Nordentoft, I.; Algaba, F.; Hoyer, S.; Uhløi, B.P.; Vang, S.; Reinert, T.; Hermann, G.G.; Mogensen, K.; et al. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. *Cancer Cell* **2016**, *30*, 27–42.
- McConkey, D.J.; Choi, W. Molecular Subtypes of Bladder Cancer. *Curr. Oncol. Rep.* **2018**, *20*, 77.
- Sanli, O.; Dobruch, J.; Knowles, M.A.; Burger, M.; Alemozaffar, M.; Nielsen, M.E.; Lotan, Y. Bladder cancer. *Nat. Rev. Dis. Primers* **2017**, *3*, 17022.
- Weiß, S.; Hallmann, S.; Koch, S.; Eidt, S.; Stoeck, R.; Veltrup, E.; Roggisch, J.; Wirtz, R.M.; Ecke, T.H. Identifying the Molecular Mechanisms Contributing to Progression, Metastasis, and Death in Low-grade Non-muscle-invasive Bladder Cancer: A Case Report. *Eur. Urol. Open Sci.* **2021**, *27*, 29–32.
- Lopez-Beltran, A.; Montironi, R. Non-invasive urothelial neoplasms: According to the most recent WHO classification. *Eur. Urol.* **2004**, *46*, 170–176.
- Montironi, R.; Lopez-Beltran, A. The 2004 WHO classification of bladder tumors: A summary and commentary. *Int. J. Surg. Pathol.* **2005**, *13*, 143–153.